The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
TCT 2021 | Impact of MMRD and ELN genetic classification in outcomes for patients with AML underoging alloHCT
Muhammad Husnain, MD, University of Arizona, Arizona Cancer Center, Tucson, AZ, discusses the impact of pre-transplant molecular measurable residual disease (MMRD) and European Leukemianet (ELN) genetic classification in clinical outcomes for acute myeloid leukemia (AML) patients undergoing allogeneic stem cell transplantation (alloHCT). This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
